Category: Clinical Research

Home / Clinical Research
First PSMA-Targeted PET Imaging Agent Approved by FDA for Men With Prostate Cancer
Post

First PSMA-Targeted PET Imaging Agent Approved by FDA for Men With Prostate Cancer

By: JNCCN 360 StaffPosted: Wednesday, December 2, 2020 On December 1, the U.S. Food and Drug Administration approved the radioactive diagnostic agent gallium 68 PSMA-11 (Ga 68 PSMA-11), the first drug for PET imaging of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer. Ga 68 PSMA-11 is indicated for patients with suspected prostate...

Reduction in Oral Mucositis with Avasopasem Manganese
Post

Reduction in Oral Mucositis with Avasopasem Manganese

ROMAN: Reduction in Oral Mucositis with Avasopasem Manganese (GC4419) – Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer STUDY SPONSOR: Galera Therapeutics, Inc. STUDY TYPE: Supportive Care METHODOLOGY: GTI-4419-301 is a randomized, double-blind, placebo-controlled, multi-center international studyconducted to evaluate GC4419 administered IV to reduce the incidence and severity of...

Debio 1143-SCCHN-301
Post

Debio 1143-SCCHN-301

Randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combo with platinum-based chemo and standard fractionation IMRT in patients with locally advanced squamous cell carcinoma of the head and neck, suitable for definitive chemoradiotherapy (TrilynX). Squamous cell carcinoma of the head and neck (SCCHN) is the 6th most common cancer worldwide. More than half...

QUILT 3.055 Study – Multiple Solid Tumor Cancers
Post

QUILT 3.055 Study – Multiple Solid Tumor Cancers

QUILT-3.055: A Phase 2b, Single-Arm, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment with PD-1/PD-L1 Immune Checkpoint Inhibitors.     DRUGS: N-803 (aka ALT-803) + PD-L1 t-haNK suspension for infusion This study is designed to treat multiple solid tumor cancers. This type of study is done because of how the...

LPNV201: Treatment of Chemo Induced Nausea/Vomiting
Post

LPNV201: Treatment of Chemo Induced Nausea/Vomiting

A Randomized, Dose-ranging, Open-label, Parallel Group Study to Assess the Efficacy, Safety and Pharmacokinetics of Palonosetron HCl Buccal Film versus IV Palonosetron 0.25 mg (ALOXI®) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Moderately Emetogenic Chemotherapy Not all clinical research we do here at the Gettysburg Cancer Center is specifically for...

Treatment of Chemo Induced Myelosuppression
Post

Treatment of Chemo Induced Myelosuppression

A Phase 3 Randomized, Double-blind Trial of Trilaciclib versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer Some cancer treatments can suppress the production blood cells that we need to be healthy. One such cancer treatment used to treat colorectal cancer is a regimen that uses a combination of folinic acid (leucovorin), fluorouracil (5FU),...

Lung Cancer Genomic Testing (EGFR, KRAS, ALK)
Post

Lung Cancer Genomic Testing (EGFR, KRAS, ALK)

Medical oncologist Marc Kris has been a key player in helping bring personalized medicine to people with lung cancer. He leads a research team working to find new genetic targets in cancer cells and to test anticancer medicines that specifically attack the lung cancers driven by these molecular changes.

Patient Information on Clinical Studies
Post

Patient Information on Clinical Studies

Mission Statement For over a quarter of a century The Gettysburg Cancer Center has been committed to providing cancer care in a community-based setting close to home. Our all-encompassing oncology and hematology programs provide a complete range of diagnosis, treatment, and follow-up care. Our caring and educated staff remains dedicated to providing insightful, compassionate care...

Merck Study – Head and neck squamous cell carcinoma
Post

Merck Study – Head and neck squamous cell carcinoma

A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and immunotherapy (PD-1/PD-L1 inhibitors) (LEAP-009) We are...

BASKET Study – Covers multiple solid tumor cancer types
Post

BASKET Study – Covers multiple solid tumor cancer types

An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) This study is designed to treat multiple solid tumor cancers. This type of study is done because of how the drug is expected to work against cancer. This study will enroll...